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Abstract: Prostate cancer is the third highest cause of male mortality in the developed world, with
the burden of the disease increasing dramatically with demographic change. There are significant
limitations to the current diagnostic regimens and no established effective screening modality. To this
end, research has discovered hundreds of potential ‘biomarkers’ that may one day be of use in
screening, diagnosis or prognostication. However, the barriers to bringing biomarkers to clinical
evaluation and eventually into clinical usage have yet to be realised. This is an operational challenge
that requires some new thinking and development of paradigms to increase the efficiency of the
laboratory process and add ‘value’ to the clinician. Value comes in various forms, whether it be a
process that is seamlessly integrated into the hospital laboratory environment or one that can provide
additional ‘information’ for the clinical pathologist in terms of risk profiling. We describe, herein,
an efficient and tissue-conserving pipeline that uses Tissue Microarrays in a semi-automated process
that could, one day, be integrated into the hospital laboratory domain, using seven putative prostate
cancer biomarkers for illustration.
Keywords: biomarker discovery; tissue microarray; automated workflow; clinical management;
morphology-guided analysis
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1. Introduction
1.1. Prostate Cancer
Prostate cancer (PCa) is the third highest cause of male mortality in the developed world. In the
UK, more than 37,000 cases of PCa are diagnosed per year, making up 25% of all male cancer
diagnoses [1,2]. Incidence increases dramatically with age with an estimate of 155 cases per 100,000 men
at age 55 and 751 cases per 100,000 men at age 75 [3]. As male lifespan increases, it is predicted that
PCa incidence will contribute significantly to the predicted doubling of cancer incidence by 2030 [4].
The one established biochemical test is Prostate-specific antigen (PSA), otherwise known as
Kallikrein-related peptidase 3 (KLK3). It is often combined with digital rectal examination and
various forms of imaging for both screening and diagnosis. Currently, a PSA cut-off of 4 ng/mL
is used to direct patients towards biopsy. This provides a specificity of 93.8% but with a heavily
compromised sensitivity of only 20.5% [5,6]. Additionally, PSA can be falsely raised in conditions such
as Benign Prostatic Hyperplasia, after infections, or post-ejaculation. Diagnosis is ultimately based on
biopsy and histology, which in itself has a 20% false negative rate based on sampling location [7–9].
This has prompted debate about alternative biopsy techniques as well as criticism of the histological
categorisation of PCa, or Gleason scale, which is based on a pathologist visually scoring the two most
dominant areas of malignancy which are summed together. This is particularly problematic for those
with the score of 7, where 4 + 3 has worse outcomes than 3 + 4 [10–12]. There is also debate about
using Magnetic Resonance Imaging (MRI) for screening, but current cost and access are major barriers
to widespread implementation.
The primary goal, then, is to find new biomarkers that are more reliable and more predictive than
PSA. However, translational research to take putative biomarkers from the laboratory to clinical trial
faces major hurdles (elaborated below). A secondary goal, then, for biomarker research must be to
find operational strategies that will enhance the speed of biomarker translation, increase the number
of donated samples, and in parallel, increase value for clinical pathologists. We envisage this occurring
through creating cheaper and more efficient laboratory processes that can be brought nearer to the
patients. In this study, we have developed such a pipeline to demonstrate potential gains in biomarker
research efficiency using seven putative biomarkers from prostate tissue.
1.2. Biomarker Research in Prostate Cancer
An ideal set of disease biomarkers should identify the maximum number of true positive
cases (sensitivity) with the fewest false positives (specificity) in a population. Biological molecules
(genes, proteins, or biochemicals) rarely show maximum sensitivity with minimal false positive
rates for complex diseases such as cancer [13]. The goal of biomarker research is to be able to
differentiate between low and high-risk PCa. The National Cancer Institute—Early Detection Research
Network (NCI–EDRN) identified five phases of biomarker development from discovery to clinical
implementation (Table 1) [14]. Potential biomarkers can be collected from various methods and sources.
‘Invasive’ methods include prostatectomies or biopsy and ‘minimally/non-invasive’ methods include
body fluids (serum, plasma, urine, prostatic fluid, and semen). Samples from the former group have
the advantage of providing direct analysis of a tumour but are invasive and more challenging in terms
of sample preparation. Body fluids have the benefit of being minimally, or non-invasive, and less
challenging to prepare but have the drawback of having a lower volume of potential biomarkers
hidden amidst a large abundance of proteins that can mask discovery [15]. There are specific benefits
and drawbacks to each medium, which is well described in the review by Tonry et al. [16].
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Table 1. Phases of biomarker research with burden of tissue and samples (Adapted from Rifai et al. [14]).
Phase Description Samples/Tissue No. ofAnalytes
No. of
Samples
I Discovery: Identifyingcandidate biomarkers
Proximal fluids
Cells line supernatants
Animal model plasma
‘Gold standard’ human plasma
(reduced biological variation)
1000s 10s
II
Qualification: Confirm differential
abundance of candidates in
human plasma
‘Gold standard’
Human plasma (reduced
biological variation)
30–100 10s
III Verification: Begin to assess specificityof candidates
Population-derived human
plasma (normal
biological variation)
10s 100s
IV/V
Validation and clinical assay
development: Establish sensitivity
and specificity, assay optimisation
Population-derived human
plasma (normal
biological variation)
4–10 Many 1000s
Techniques for biomarker discovery include gel-based methods [17] and mass-spectrometry [18];
laboratory evaluation and qualification can involve techniques utilising antibodies, nanotechnology
immunosensors, and aptamers [16]. Importantly, when considering biomarker research, one should
consider whether the technique of discovery can be adapted to add value to the clinician or pathologist
who may, one day, utilise the biomarker in the clinical environment. An example of this approach is
the use of non-invasive office-based biomarker tests using urine for the screening of bladder cancer,
with one major advantage being rapid results for the General Practitioner and patient [19].
The important fact to clarify in future biomarker research is the benefit of this research to clinicians
and to researchers. For clinicians, putative biomarkers derived from body fluids may one day lead
to a robust PCa screening programme, whilst biomarkers from tissue provides risk stratification and
prediction of recurrence. For the scientist, each type of sample is useful. Body fluids allow for research
of systemic associative molecules related to the process of carcinogenesis, whilst histologic material
provides an opportunity for morphology-guided analysis focusing on tumour cells, peri-tumour cells,
and surrounding tissue architecture.
While the ultimate goal of biomarker research is to find new biomarkers that can be brought
to clinical use, the twin problems of a lack of sample donation and inefficiency of testing suggests
a new paradigm for biomarker research to tackle these issues is needed. Defining a set of efficient
and cost-effective techniques that can be potentially integrated into the hospital-environment may
offer clinicians rapid results and solve the problem of a lack of samples for biomarker research.
Tissue microarrays (TMA) hold promise in achieving this, and we describe here a pipeline for
TMA-based antibody biomarker evaluation that can be used for any of the four phases of biomarker
evaluation from discovery to validation.
1.3. Tissue Micro Arrays for Discovery
TMA is a powerful and high-throughput technology for the analysis of many paraffin-embedded
tissue cores on a single slide. As all cores are treated identically in the preparatory phase of each
slide, technical inter-slide variability is reduced, improving standardisation. Many tissue cores can
be assembled on a single array leading to a significant economy of scale, reducing the costs of
immunohistochemical markers by staining many individual’s samples at the same time. Historically,
TMA analysis was conducted using visual measurement of criteria such as stain intensity, distribution
and stained-cell count, leading to various comparative scoring systems. Visual examination, however,
is the leading limitation in TMA analysis [20]. In the present study, we describe a technique using
TMA immunohistochemical staining, captured on a Zeiss Axioscan Z1 (Zeiss, Cambridge, UK) slide
Diagnostics 2018, 8, 49 4 of 15
scanner, and analysed using a computerised semi-automated image analysis pipeline, producing an
objective, replicable and rapid system of biomarker evaluation.
1.4. Putative Biomarkers
We tested our pipeline using seven putative biomarkers, which we have studied previously in our
laboratory and have existing empirical literature connecting the molecule to cancer and genito-urinary
carcinogenesis (Table 2). The potential biomarkers analysed in the present study were: Mitochondrial
membrane ATP synthase F1 subunit 1 (ATP5A1), Acyl-coenzyme A Binding protein (ABCP, also known
as Diazepam-binding inhibitor (DBI)), 60 kDa Heat Shock Protein (HSP60), Eukaryotic Translation
Initiation Factor 3 subunit 1 (IF3EI or EIF3I), Integral Membrane Protein 2B (ITM2B), Myosin Light
Chain 6 (MYL6), and Polyadenylate-binding protein 3 (PABPC3).
Table 2. Investigated biomarkers and their empirical evidence relating to cancer pathogenesis.
Putative Biomarkers
ATP5A1
ATP5A1 is one of two subunits of the mitochondrial
ATP synthase, which catalyses ATP synthesis during
oxidative phosphorylation. Subunits of ATP synthase
are implicated in various malignancies including
Clear Cell Renal Cancer, Thyroid, and Prostate
malignancy [21]. Research with prostate cancer cells
has suggested a role for ATP synthase subunits in
protective autophagy as well as binding partners for
metastasis-associated membrane proteins [22–24].
DBI or ACBP
ACBP is a protein that is involved in various
functions including steroidogenesis and peptide
hormone release [25]. It is overexpressed in lung and
hepatocellular carcinoma [26,27] and has been
suggested as a predictive marker of outcome after
chemotherapy for urothelial cancers [28]. There is
also evidence that it has a role as a secreted peptide
from prostatic epithelial cells, whose levels rise when
exposed to androgens [29,30].
HSP60
Heat shock protein 60 is a mitochondrial protein that
assists with the assembly of newly imported proteins
in the mitochondria [31]. HSP60 has a role, together
with HSP70, in antigen presentation in malignant
diseases [32], is enhanced in activity in breast
carcinoma [33], and myeloid leukaemia [34]. HSP60
is upregulated in prostate cancer and interacts with
cyclophilin D to affect mitochondrial permeability
[35–37]. It is significantly raised in prostate cancer
[38] and has overexpression in associated Gleason
score, initial serum PSA levels, and lymph node
metastasis as well as androgen independence in
locally advanced prostate cancers. Intensity and
immunoreactivity of HSP60 predict recurrence and
decreased recurrence-free survival [39].
EIF3 complex
The Eukaryotic Translation Initiation Factor (EIF) 3
multiprotein complex plays a central role in
translation initiation. IF3EI is part of EIF3 complex
along with proteins such as EIF3b. Overexpression of
EIF3b has been observed in both prostate and bladder
tumours [40]. Research suggests other eukaryotic
translation initiation factor complexes are involved in
tumour advancement in castration-resistant prostate
cancer [41–43]. Several subunits of the EIF3 protein
complex, either through upregulation or
downregulation, have been implicated in prostate
cancer tumorigenesis [44–49]. Gain in function
through the addition of the long arm of chromosome
8 is seen commonly along with a gain of EIF function
in late-stage prostate cancer in as much as 30% of
cases [50,51].
ITM2B
ITM2B (formerly BRI2) is a transmembrane protein
that processes amyloid, inhibits beta-amyloid peptide
aggregation and fibril deposition and induction of
neurone outgrowth. It is implicated in neuroblastoma
and lymphoma [52–54]. In the genitourinary system,
it has functional implications in motility and tail
formation of spermatozoa [55]. In the realm of cancer
research, its gene has been implicated as being lost in
mutations of the 13q14 chromosomal arm seen in
many sporadic prostate cancers [56].
MYL6
MYL6, one of many myosin alkali light chains that
are expressed in smooth muscle and non-muscle
tissues. There is evidence for the activation of myosin
light chain kinase as a possible mechanism by which
PCa may escape dormancy [57] as well as
phosphorylation of myosin in the regulation of
metastases [58]. Regarding the light chain protein,
there is evidence of its importance in maintaining
basal lamina matrix integrity; breach of may occur
more readily in older individuals, possibly explaining
an age-related prostate cancer risk [59].
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Table 2. Cont.
Putative Biomarkers
PABPC family
Poly(A)-binding proteins play a role in mRNA
stability and translation initiation. Evidence about
other proteins in the family, such as PABPC1,
suggests it is unregulated in gastric [60],
hepatocellular [61], and duodenal [62] carcinomas as
well as interacting with the androgen receptor, which
is the primary target for prostate cancer
treatment [63].
2. Materials and Methods
2.1. Ethics and Specimens
Ethical approval for the use of human prostate tissue in cancer research was granted by the
committee of the University College London Joint Research Office and carried out in accordance
with the International Committee on Harmonisation of Good Clinical Practice. Archival specimens
gathered from open prostatectomies between December 1991 and April 2002 were used. Patients were
categorised into two groups. The ‘high-risk malignant’ group (HR) were patients with biochemical
relapse within two years (defined as PSA ≥ 0.2 ng mL−1), whilst those that required no further
cancer therapy and had no biochemical evidence of disease after 3 years were categorised as ‘low-risk
malignant’ (LR). Patients who had neoadjuvant chemotherapy or antiandrogen therapy were excluded.
Further details of patient selection and inclusion criteria are described in detail elsewhere (https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC3752526/). In total 82 patients were included and organised
into case pairs containing one HR and one LR, with similar sum Gleason score, preoperative PSA
level, and pathological stage subcategory (pT3a or pT3b) at the time of surgery. All samples were
examined and classified by a urological pathologist and coded anonymously to avoid bias in tissue
array construction, imaging, and analysis.
2.2. TMA Design and Construction
The TMA was constructed using formalin-fixed, paraffin-embedded tissue blocks collected from
82 patients who underwent radical prostatectomy, as described previously [64–66]. Areas of highest
Gleason grade were marked by one pathologist using a haematoxylin and eosin (H + E)-stained 3 µm
section of each tissue block. Representative, 0.6 mm diameter and 3 mm depth tissue cores were
taken from pre-defined locations using a Beechers MTA 1 (Beechers Instruments, Sun Prairie, WI,
USA) manual tissue-arrayer. Four cores were sampled from the two marked tumour locations and
four non-malignant cores were sampled from the peripheral zone for equivalence in each specimen.
Four replicate TMA blocks were constructed, containing all 82 samples. For positive and negative
controls, samples of malignancies in organs other than prostate were included as cores on the tissue
block in randomly selected locations. Six to eight micrometre tissue array (TMA) sections were taken
for clinical re-characterisation of each core by a urological histopathologist (~78% diagnosed as Gleason
grade 3 + 4 or 4 + 3).
2.3. Immunohistochemical Staining of Proteins
Staining protocols have been described in detail previously [67]. Standard antigen retrieval
was performed on 3 µm sections of each TMA block before individual immunostaining with
seven antibodies ATP5A1 (ab14748), DBI (ab16806), HSP60 (ab59457), IF3EI (ab64900), ITM2B
(ab89352), MYL6 (ab84349), and PABPC3 (ab68090) all from Abcam (Cambridge, UK) using a
3,3-diaminobenzidine (DAB) staining protocol on an automated Bond MAX™ machine (Leica
Biosystems, Milton Keynes, UK) and a Bond polymer detection system kit at high contrast, per
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manufacturer’s protocols (DS9173). For negative controls, the primary antibody was either replaced
with IgG matched controls or omitted.
2.4. 3,3-Diaminobenzidine (DAB) Stain Imaging and Signal Quantification
Each TMA slide was imaged on an AxioScan Z1 slide scanner (Zeiss, UK) at 40× magnification
and an image of each TMA core was exported for analysis using ImageJ software (NIH, Bethesda, MD,
USA). A random selection of tissue cores (n = 10 HR, n = 10 LR) was used as a training set to select
two-pixel value thresholds based on a linear regression model. The first threshold encompassed the
quantity of tissue (AmtT) in the image by measuring any non-background pixels; the second threshold
encompassed the amount of DAB signal (AmtS) in the image. The quantity of tissue present in each
image was calculated using a macro written in ImageJ. Once selected, the same threshold values
were applied to every image stained with a single antibody. The amount of DAB signal expressed
in each tissue core was calculated as AmtS/AmtT and is used for statistical tests of significance of
difference using a Mann-Whitney-U test. Mountain plots were constructed using Origin (OriginLab,
Northampton, MA, USA) to illustrate differences in expression between HR and LR cores. Receiver
operating characteristics (ROC) curves were constructed in Medcalc software to evaluate the propensity
of the protein as a biomarker of malignancy.
2.5. Whole Pipeline in Sequence
The entire process described above from initial processing of TMA to eventual results output
occurred in a linear process within several days and with further efficiency gains, could be undertaken
within a single working day. We assembled four arrays, but this can be changed, and it is quite
conceivable that it could be scaled up dramatically, or alternatively, a single core could be processed in
each run, reflecting the process of receipt of individual specimens in the hospital pathology laboratory.
The statistical techniques are also automated, running in sequence to image capture. The fixed costs of
the process are an initial investment in equipment with variable costs being those of antibody stains.
3. Results
Representative images of the seven proteins in TMA core samples are shown in Figure 1.
Quantitative analysis of chromophore integrated density performed in ImageJ revealed higher
expression of each protein in HR cores compared with LR tissue cores (Table 3).
Main Findings
Changes in expression have been illustrated in mountain plots (Figure 2), where clear differences in
expression can be seen between HR tissue cores (red) and LR tissue cores (green). A Mann–Whitney-U
test revealed statistically significant differences between HR and LR tissue core expression for ATP5A1
(p < 0.001), DBI (p < 0.001), HSP60 (p < 0.001), IF3EI (p < 0.001), ITM2B (p < 0.001), MYL6 (p = 0.0012),
and PABPC3 (p < 0.001). Comparing each of the tested proteins for their predictive ability to distinguish
between HR and LR tissue cores (Table 3) revealed that ATP5A1 had the highest sensitivity (71.43)
and specificity (78.05). ROC curve analysis was carried out to characterise the potential clinical utility
of these proteins as biomarkers of malignancy in PCa specimens (Figure 3, Supplementary Table S1).
The positive post-test probability ranged from 0.67 to 1.82% (LR+ = 1.463–3.950) and the negative
post-test probability ranged between 0.12–0.31% (LR− = 0.2630–0.678). The area under the curve
(AUC) of the ROC curve was highest in ATP5A1 (0.806 ± 0.026) and lowest in MYL6 (0.61 ± 0.034)
with all other biomarkers demonstrating a range of AUC between these two values. The AUC indicates
a greater likelihood of being able to distinguish between disease than other proteins tested, and a
higher AUC would generally make a protein a better candidate for putative biomarker. A logistic
regression model, performed using MedCalc software, shows an increase in diagnostic performance
can be achieved by incorporating data from both ATP5A1 and HSP60. The use of both sets of data
resulted in 71.85% of cases being correctly classified (AUC = 0.822 ± 0.025, data not shown in Table 3).
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and PABPC3 (0.740 ± 0.030). Sensitivity and specificity are measured using the Youden index to 
Figure 1. Representative images of a high-risk malignant (HR) and low-risk malignant (LR) prostate
cancer tissue core (0.6 mm diameter) taken from sister sections of a tissue array block. Tissue array
sections were stained using a 3,3-diaminobenzidine (DAB) protocol for the following proteins
(ATP synthase F1 subunit 1 (ATP5A1), Diazepam-binding inhibitor (DBI), 60 kDa Heat Shock
Protein (HSP60), IF3EI, Integral Membrane Protein 2B (ITM2B), Myosin Light Chain 6 (MYL6),
and Polyadenylate-binding protein 3 (PABPC3)).
Table 3. Evaluation of seven putative biomarkers.
Protein Sensitivity Specificity Criteria > AUC
ATP5A1 71.43 78.05 3.37 0.806 ± 0.026
HSP60 59.18 88.62 3.29 0.800 ± 0.026
PABPC3 63.95 78.86 3.26 0.740 ± 0.030
ITM2B 65.99 72.36 3.16 0.738 ± 0.30
IF3EI 68.71 66.61 3.10 0.720 ± 0.031
DBI 78.23 57.72 2.68 0.715 ± 0.031
MYL6 42.26 73.17 3.77 0.610 ± 0.034
Predictive ability to distinguish between HR and LR tissue cores. Proteins are sorted by
descending under the curve (AUC) (area under the receiver operating characteristics (ROC)
curve) revealed that ATP5A1 had the highest AUC value (0.806 ± 0.026), followed by HSP60
(0.800 ± 0.026) and PABPC3 (0.740 ± 0.030). Sensitivity and specificity are measured using the Youden
index to show the potential effectiveness of the marker. Values calculated from data in Figure 3.
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NB: Sensitivity and specificity are listed along with respective cut-off values and likelihood ratios in
Supplementary Table S1.
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Figure 2. Mountain Plots. The total area of DAB stain and the total quantity of tissue present in each
tissue core (pixels) was measured using a high throughput, semi-automated protocol using ImageJ
software. Mountain plots illustrating the amount of DAB signal per amount of tissue in each tissue
core. Red bars represent HR cores arranged in ascending order and green bars are LR tissue cores
arranged in descending order. Plots were constructed in Origin (OriginLab, Northampton, MA, USA)
software. Significant differences between protein expression in HR and LR tissue cores were observed
in all proteins tested: ATP5A1 (p < 0.001), DBI (p < 0.001), HSP60 (p < 0.001), IF3EI (p < 0.001), ITM2B
(p < 0.001), MYL6 (p = 0.0012), and PABPC3 (p < 0.001).
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Figure 3. ROC Curves. ROC curves for the seven putative biomarkers (ATP5A1, DBI, HSP60, IF3EI,
ITM2B, MYL6, and PABP 3) that were tested in this study were constructed to evaluate the diagnostic
accuracy of each protein to differentiate betwe n HR and LR tissue cores. Val es for AUC, sensitivity
and spe ifi ity re given in Table 3. Sensitivity and specificity are listed along with resp ctive cut-off
values and likelihood ratios in Supplementary Tabl S1.
4. Discussion
4.1. Image Analysis and Implications for Future Study
The use of a TMA features several advantages over other techniques in biomarker research, namely
each tiss e sample has been subj cted to ide tical c nditions, enabling simultaneous comp ison
of potentially several hundred tissue samples [68]. On top of this, a semi-automated, reproducible
method through computer analysis of stain intensity increases the objectivity of this ystem of an lysis.
Overall, th issues of heterogeneity of staining and subjective visual xaminati n with inter- and
intra-observer differences are obviated [69].
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4.2. Challenges in Prostate Cancer Biomarker Research
At present, there are several bottlenecks to the conversion of putative PCa (indeed any cancer)
biomarkers to usable and routinely employed clinical tests. PSA took 10 years to transition from
laboratory biomarker to clinical blood test [70], by which point its limitations were well known.
Indeed, there have been over 200 PCa biomarkers discovered, but none has completed clinical
evaluation [71–78]. There are several barriers to improvements in this process. The largest hurdle is
volunteer recruitment in the final stage of clinical evaluation; however, laboratory limitations also exist,
including the techniques of testing, the ‘silo-ing’ effect of laboratories, and operational ‘distance’ of the
biomarker research facilities. The challenge of increasing clinical volunteer recruitment is beyond the
scope of this article, but greater inter-institutional collaboration and ‘visibility’ of biomarker research at
primary and secondary care level may enhance the awareness of biomarker research amongst healthy
and diseased individuals, potentially increasing recruitment. These actions are likely to require greater
scientist, clinician, and policymaker collaboration to realise. While this study is a biomarker evaluation
project, the methodology and experience gained from developing our processes allow us to describe
operational changes and envisage a paradigm of a more efficient ‘biomarker laboratory’, which we
will describe here.
The first technical improvement we would describe is the increased utilisation of tissue-conserving
methods such as TMA alongside multiplex-antibody labelling. While this will not increase statistical
power, it increases the output of proteomic data from each specimen and conserves tissue.
The second issue is the ‘silo-ing’ effect and resource utilisation of the laboratories themselves.
At present, the different steps of biomarker research are often carried out by different specialists
often in different locations using instruments, tools, and software packages that are behind walls of
commercial licensure. Borrowing theories from industry, the idea of ‘re-engineering’ proposes that
specialised work should be centred around outcomes rather than people [79]. The case here being
that focusing on the turn-around time of specimens to results and combining specialists into one
biomarker-focused team could yield a significantly higher output and more and efficient process.
Additionally, new technology such as automated TMA production, staining, microscopy, and iterative
machine learning algorithms for image analysis may lead to an operational flow process of less than
24 h from the point of receipt of specimens.
The final aspect of operational improvement is the integration of the biomarker laboratory into
the clinical space. This will yield both immediate benefits in terms of reductions in cost and time lost
through transport as well as increasing the ‘presence’ of the researchers. This latter point may, through
closer clinician-researcher ties, yield greater specimen collection as well as participant recruitment.
An eventual possibility is the dual utilisation of techniques such as TMA within the clinical laboratory
both for diagnostic histopathological purposes and research simultaneously, yielding gains through
greater utilisation and data gathering for biomarker research. This is somewhat analogous to the
multi-vehicular assembly line employed in modern automotive manufacturing, where greater yields in
outcomes are achieved through reduction of redundancy. All three of these improvements, if realised,
would reflect the importance of better planning and integration between researchers and clinicians for
the goal of cancer biomarker research [80].
4.3. Other Future Scenarios
We have here only described one suggestion of how TMA and imaging techniques used in our
laboratory may improve biomarker research efficiency, but other areas of advancement are also of
interest. Use of non-invasive body fluid, such as blood and urine, is an exciting mode of increasing
volunteer recruitment as is the prospect of bringing the testing to the primary care physician’s office
using nanotechnology-based data collection methods [16]. Many paradigms exist for improvements
in this field of research but different tissue sources and technologies aside, the main goal must be
improvements in the design and execution of the operational process.
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5. Conclusions
The field of PCa biomarker research is a moving target with new biomarkers discovered constantly
but with a long delay in bringing tests to the doctor’s office. Each new discovery prompts research
into further biomarkers through their biochemical relationships, with the hope that, eventually, some
of these biomarkers can reach the clinical validation stage. The main barriers to achieving this are the
speed of laboratory processes and sample donation, which requires volunteer participants. We believe
the solution to these limitations is to devise more efficient processes and reduce the barriers to voluntary
participation, which will enable the biomarker research process to enter the clinical environment nearer
to the patients. To demonstrate a more efficient process, we have identified in the present study, several
putative biomarkers using a method that is rapid, objective and specimen conserving. The low-cost
technique described has the possibility of being easily scaled up in volume, further refined through
automation and importantly, brought closer to the clinicians. All these factors may help contribute
towards a more integrated and efficient paradigm of a ‘biomarker laboratory’.
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